Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present virtually at the 7th Cell and Gene Therapy In-Depth Focus Summit taking place from June 27-28, 2024, in Beijing, China.
The presentation will be available on Medigene´s website following the conference: https://medigene.com/science/abstracts/
Virtual presentation:
7th Cell and Gene Therapy In-Depth Focus Summit 2024
https://www.bagevent.com/event/8751058
Location: Crown Hotel Youtang, Beijing, China (virtual presentation)
Date and time: June 27, 2024; 4.30 – 5pm local time
Presenter: Kirsty Crame, MD, VP Clinical Strategy & Development
Title: MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory Switch Protein, Advancing to the Clinic
The presentation will feature the Company’s lead program MDG1015, a first-in-class third-generation T cell receptor-engineered T cell (TCR-T) therapy. This therapy targets NY-ESO-1/LAGE-1a (New York oesophageal squamous cell carcinoma 1 / L Antigen Family Member-1a) and is enhanced with the PD1-41BB costimulatory switch protein. The first-in-human trial for MDG1015 is planned for gastric cancer, ovarian cancer, myxoid/round cell liposarcoma, and synovial sarcoma, and is on track for Investigational New Drug (IND) filing in Q3 2024 and Clinical Trial Application (CTA) filing in Q4 2024.
— end of press release —
About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, armor and enhance these T cell receptor engineered (TCR) -T cells to create best-in-class, differentiated TCR-T therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its own therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is on track for IND filing in Q3 2024 and CTA filing in Q4 2024. For more information, please visit https://medigene.com/
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
